Option Care Selected as the Home and Alternate Site Infusion Provider for Newly Approved Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection
Published: Mar 08, 2018
Option Care will provide personalized care management support to patients receiving Trogarzo™ infusions in addition to their current HIV treatment regimen. “Driving superior clinical value through nursing services, pharmacy management and patient support enable us to deliver optimal outcomes,” said Matt Deans, Vice President, Business Development at Option Care. “Our ability to provide unmatched home and alternate treatment site infusion services allow us to partner with innovators bringing groundbreaking therapies like Trogarzo™ to market. In addition, the ability to offer Trogarzo™ extends our market leadership in the provision of infusion therapies within Infectious Disease.”
Approved by the FDA in March 2018, Trogarzo™ is marketed and distributed by Theratechnologies Inc. A high percentage of the HIV+ population faces ongoing challenges with the effectiveness of their treatment. Trogarzo™ represents a critical new treatment that provides an option to those patients not responding to conventional therapies who are left with limited options.
About Option Care
Option Care Enterprises, Inc. (Option Care) is the nation’s largest independent and most trusted provider of home and alternate treatment site infusion services. An industry leader, the company draws on nearly 40 years of clinical care experience to offer patient-centered therapy management. Option Care’s signature Home Infusion Plus services include the clinical management of infusion medicines, nursing support and care coordination. Option Care’s multidisciplinary team of more than 1,800 clinicians – including pharmacists, nurses and dietitians – are able to provide home infusion service coverage for nearly all patients across the United States needing treatment for complex and chronic conditions. Learn more at www.OptionCare.com.
About Trogarzo™ (ibalizumab-uiyk) Injection
Trogarzo™ is a humanized monoclonal antibody for the treatment of multidrug resistant HIV-1 infection. Trogarzo™ binds primarily to the second extracellular domain of the CD4+ T receptor, away from major histocompatibility complex II molecule binding sites. It prevents HIV from infecting CD4+ immune cells while preserving normal immunological function.
IMPORTANT SAFETY INFORMATION
Trogarzo™ is a prescription HIV medicine that is used with other antiretroviral medicines to treat human immunodeficiency virus-1 (HIV-1) infections in adults.
Trogarzo™ blocks HIV from infecting certain cells of the immune system. This prevents HIV from multiplying and can reduce the amount of HIV in the body.
Before you receive Trogarzo™, tell your healthcare provider if you:
- are pregnant or plan to become pregnant. It is not known if Trogarzo™ may harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if Trogarzo™ passes into breast milk.
Tell your healthcare provider about all the medicines you take, including all prescription and over-the-counter medicines, vitamins, and herbal supplements.
Trogarzo™ can cause serious side effects, including:
Changes in your immune system (Immune Reconstitution Inflammatory Syndrome) can happen when you start taking HIV-1 medicines. Your immune system might get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your health care provider right away if you start having new symptoms after starting your HIV-1 medicine.
The most common side effects of Trogarzo™ include:
Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Trogarzo™. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to 1-833-23THERA (1-833-238-4372).
For more information, including full Prescribing Information and Patient Information, please visit www.trogarzo.com/.